Press releases
* (R) = Regulatory press releases
Mar 25, 2025
Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.
Mar 10, 2025
Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited
Mar 6, 2025
Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
Feb 21, 2025